N-hydroxy-2-methoxybenzenesulfonamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-hydroxy-2-methoxybenzenesulfonamide
• 英文别名: N-Hydroxy-2-methoxybenzene-1-sulfonamide
• 化学式: C₇H₉NO₄S
• mdl: MFCD21882812
• 分子量: 203.219
• InChiKey: SIHWDTFBKAWHNR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  84
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-hydroxy-2-methoxybenzenesulfonamide 以 水 为溶剂， 生成 一氧化二氮
  参考文献：
  名称：

  WO2007/109175

  摘要：

  公开号：
• 作为产物：
  描述：

  2-甲氧基苯磺酰氯 在 4-二甲氨基吡啶 、 盐酸羟胺 作用下， 以 吡啶 为溶剂， 反应 0.08h， 以37%的产率得到N-hydroxy-2-methoxybenzenesulfonamide
  参考文献：
  名称：

  Piloty’s acid derivative with improved nitroxyl-releasing characteristics

  摘要：

  Recent studies have shown that nitroxyl (HNO) ((HNO)-H-1/(NO)-N-3 ), which is the one-electron-reduced form of nitric oxide (NO), has unique biological activities, especially in the cardiovascular system, and HNO-releasing agents may have therapeutic potential. Since few HNO donors are available for use under physiological conditions, we synthesized and evaluated a series of Piloty's acid (PA) derivatives and evaluated their HNO-releasing activity under physiological conditions. N-Hydroxy-2-nitrobenzenesulfonamide (17) was the most efficient HNO donor among our synthesized PA derivatives, including the lead compound, 2-bromo-N-hydroxybenzenesulfonamide (2). The high HNO-releasing activity is suggested to be due to electronic and steric effects. Compound 17 may be a useful tool for biological experiments. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.02.062

文献信息

• PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS
  申请人：CARDIOXYL PHARMACEUTICALS

  公开号：US20150366977A1

  公开（公告）日：2015-12-24

  The present disclosure provides nitroxyl donating pharmaceutical compositions comprising N-substituted hydroxylamine derivatives. The compositions are highly efficacious in treating cardiovascular diseases (e.g., heart failure), have a suitable toxicological profile, and are sufficiently stable for intravenous or oral administration.

  本公开提供了含有N-取代羟胺衍生物的亚硝酰基供体药物组合物。该组合物在治疗心血管疾病（如心力衰竭）方面具有高效性，具有适当的毒理学特性，并且对于静脉或口服给药具有足够的稳定性。
• N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS
  申请人：The Johns Hopkins University

  公开号：EP3124471A1

  公开（公告）日：2017-02-01

  The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.

  本发明涉及N-羟基磺酰胺衍生物，该衍生物可在生理条件下捐献硝酰（HNO），并可用于治疗和/或预防对硝酰治疗有反应的疾病或病症的发生和/或发展，包括心力衰竭和缺血/再灌注损伤。新型 N- 羟基磺酰胺衍生物可在生理条件下以可控速率释放 NHO，HNO 释放速率可通过改变 N- 羟基磺酰胺衍生物上官能团的性质和位置来调节。
• Pharmaceutical compositions comprising nitroxyl donors
  申请人：Cardioxyl Pharmaceuticals, Inc.

  公开号：US10245249B2

  公开（公告）日：2019-04-02

  The present disclosure provides nitroxyl donating pharmaceutical compositions comprising N-substituted hydroxylamine derivatives. The compositions are highly efficacious in treating cardiovascular diseases (e.g., heart failure), have a suitable toxicological profile, and are sufficiently stable for intravenous or oral administration.

  本公开提供了由 N-取代的羟胺衍生物组成的硝基捐献药物组合物。这些组合物在治疗心血管疾病（如心力衰竭）方面疗效显著，具有合适的毒理学特征，并且足够稳定，可用于静脉注射或口服给药。
• Method of administering nitroxyl donating compounds
  申请人：Cardioxyl Pharmaceuticals, Inc.

  公开号：US11083704B2

  公开（公告）日：2021-08-10

  The disclosed subject matter provides methods of using nitroxyl donating compounds and pharmaceutical compositions comprising such compounds in a dose escalation regimen.

  所公开的主题提供了在剂量递增方案中使用硝基供体化合物和包含此类化合物的药物组合物的方法。
• NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION
  申请人：Cardioxyl Pharmaceuticals, Inc.

  公开号：EP2504003B1

  公开（公告）日：2016-11-09